Market Performance: The Hang Seng Index (HSI) rose by 359 points (1.4%) to close at 26,518, with significant gains also seen in the HSTI and HSCEI, which increased by 156 points (2.5%) and 152 points (1.6%) respectively, and a market turnover of $288.77 billion.
Active Heavyweights: Notable stock performances included Alibaba (BABA) up 9.2% to $174, Xiaomi (XIAOMI) up 2.6% to $56.9, and Tencent (TENCENT) up 2% to $648.5, with substantial short selling activity across these stocks.
HSI & HSCEI Constituents: SMIC saw a significant rise of 5.7% to $76.75, while other notable gainers included Xinyi Solar and Kuaishou, both showing strong percentage increases, whereas Giant Biogene experienced a notable decline of 12%.
Short Selling Trends: The short selling ratios varied widely among stocks, with some like Xinyi Glass and Kuaishou showing high ratios, indicating varying levels of investor sentiment and market speculation.
Wall Street analysts forecast 00388 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 00388 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
Wall Street analysts forecast 00388 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 00388 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
Current: 438.600
Low
Averages
High
Current: 438.600
Low
Averages
High
Citi
Citi Research
Buy
downgrade
$515 -> $505
Al Analysis
2025-12-09
Reason
Citi
Citi Research
Price Target
$515 -> $505
Al Analysis
2025-12-09
downgrade
Buy
Reason
Citi Research maintained a "Buy" rating for HKEX despite slightly lowering its FY2025-2027 EPS forecasts by 1%. This adjustment was primarily due to a reduced average daily turnover forecast for Hong Kong stocks, which was lowered by 1-3%. Consequently, the target price for HKEX was also reduced from $515 to $505.
HSBC
HSBC Global Research
maintain
$530
2025-11-13
Reason
HSBC
HSBC Global Research
Price Target
$530
2025-11-13
maintain
Reason
The analyst rating from HSBC Global Research for HKEX is based on the belief that the acquisition of a 20% stake in CMU OmniClear Holdings for $455 million is a positive move for the company. They noted that while the transaction will have a limited short-term financial impact, the commercialization of CMU OmniClear could provide upside potential. Additionally, HKEX's history of driving market development through financial infrastructure enhancements suggests a promising growth potential for its financial innovation center business. As a result, HSBC maintained a "Buy" rating with a target price of $530.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for 00388
Unlock Now
DBS Research
DBS Research
Buy
maintain
$540
2025-11-07
Reason
DBS Research
DBS Research
Price Target
$540
2025-11-07
maintain
Buy
Reason
DBS Research has issued a Buy rating on HKEX due to several positive factors: strong momentum in the Hong Kong bourse, improved liquidity and investment sentiment, attractive valuations of Hong Kong tech stocks compared to other markets, and supportive government policies and stimulus measures. They have also raised their average daily turnover forecast for HKEX, indicating confidence in the market's performance. The target price remains at HKD540.
UOB Kay Hian
UOB Kay Hian
Buy
maintain
$548
2025-11-07
Reason
UOB Kay Hian
UOB Kay Hian
Price Target
$548
2025-11-07
maintain
Buy
Reason
The analyst rating from UOB Kay Hian for HKEX is a "Buy" due to a significant 56% year-over-year increase in net profit for 3Q25, which exceeded the broker's expectations by 7%. This strong performance was attributed to robust growth in core revenue, a record-breaking average daily trading volume, and strong IPO momentum. Despite a decline in net interest income, the overall positive financial results led to the decision to maintain a Buy rating and raise the target price to HKD548.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
